Hematopoietic and hematologic properties of bestatin in normal and cyclophosphamide myelosuppressed mice

JE Talmadge, PL Black, Louis Pelus, F. Abe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bestatin is a potent inhibitor of aminopeptidase, an enzyme found in abundance in the membrane of monocytes and macrophages. Following binding of bestatin to cells in the histiocytic lineage, the production of colony stimulating activity is upregulated (both in vitro and in vivo) with subsequent increases in hematopoietic and hematologic parameters. We report that the frequency and absolute numbers of CFU-GM as well as entry of CFU-GM into S phase (a measure of progenitor cell activity) is upregulated by treatment of animals with bestatin. This results in an increase in bone marrow cellularity in cyclophosphamide suppressed mice and an increase in the absolute neutrophil count in normal and suppressed mice. The therapeutic application of this hematopoietic modulator has been demonstrated in combination cyclophosphamide and bestatin therapeutic protocols. Because this indication for bestatin has only recently been recognized, few clinical studies have been undertaken utilizing appropriate surrogates of hematopoietic activity. However, preliminary clinical evidence of hematopoietic activity by this non-toxic dipeptide, as reviewed here, suggests that this may be an appropriate strategy for the treatment of myelosuppressed patients.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume44
Issue number2
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Cyclophosphamide
Granulocyte-Macrophage Progenitor Cells
Aminopeptidases
Dipeptides
Enzyme Inhibitors
Therapeutics
S Phase
Monocytes
Neutrophils
Stem Cells
Bone Marrow
Macrophages
ubenimex
Membranes

Keywords

  • bestatin / hematopoiesis / myelosuppression / CFU-GM
  • bestatine / hématopoïèse / myelosuppression / CFU-GM

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hematopoietic and hematologic properties of bestatin in normal and cyclophosphamide myelosuppressed mice. / Talmadge, JE; Black, PL; Pelus, Louis; Abe, F.

In: Biomedicine and Pharmacotherapy, Vol. 44, No. 2, 1990, p. 85-91.

Research output: Contribution to journalArticle

Talmadge, JE ; Black, PL ; Pelus, Louis ; Abe, F. / Hematopoietic and hematologic properties of bestatin in normal and cyclophosphamide myelosuppressed mice. In: Biomedicine and Pharmacotherapy. 1990 ; Vol. 44, No. 2. pp. 85-91.
@article{757bc6f78d494f0eb8e6157a4e7f4846,
title = "Hematopoietic and hematologic properties of bestatin in normal and cyclophosphamide myelosuppressed mice",
abstract = "Bestatin is a potent inhibitor of aminopeptidase, an enzyme found in abundance in the membrane of monocytes and macrophages. Following binding of bestatin to cells in the histiocytic lineage, the production of colony stimulating activity is upregulated (both in vitro and in vivo) with subsequent increases in hematopoietic and hematologic parameters. We report that the frequency and absolute numbers of CFU-GM as well as entry of CFU-GM into S phase (a measure of progenitor cell activity) is upregulated by treatment of animals with bestatin. This results in an increase in bone marrow cellularity in cyclophosphamide suppressed mice and an increase in the absolute neutrophil count in normal and suppressed mice. The therapeutic application of this hematopoietic modulator has been demonstrated in combination cyclophosphamide and bestatin therapeutic protocols. Because this indication for bestatin has only recently been recognized, few clinical studies have been undertaken utilizing appropriate surrogates of hematopoietic activity. However, preliminary clinical evidence of hematopoietic activity by this non-toxic dipeptide, as reviewed here, suggests that this may be an appropriate strategy for the treatment of myelosuppressed patients.",
keywords = "bestatin / hematopoiesis / myelosuppression / CFU-GM, bestatine / h{\'e}matopo{\"i}{\`e}se / myelosuppression / CFU-GM",
author = "JE Talmadge and PL Black and Louis Pelus and F. Abe",
year = "1990",
doi = "10.1016/0753-3322(90)90109-M",
language = "English (US)",
volume = "44",
pages = "85--91",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "2",

}

TY - JOUR

T1 - Hematopoietic and hematologic properties of bestatin in normal and cyclophosphamide myelosuppressed mice

AU - Talmadge, JE

AU - Black, PL

AU - Pelus, Louis

AU - Abe, F.

PY - 1990

Y1 - 1990

N2 - Bestatin is a potent inhibitor of aminopeptidase, an enzyme found in abundance in the membrane of monocytes and macrophages. Following binding of bestatin to cells in the histiocytic lineage, the production of colony stimulating activity is upregulated (both in vitro and in vivo) with subsequent increases in hematopoietic and hematologic parameters. We report that the frequency and absolute numbers of CFU-GM as well as entry of CFU-GM into S phase (a measure of progenitor cell activity) is upregulated by treatment of animals with bestatin. This results in an increase in bone marrow cellularity in cyclophosphamide suppressed mice and an increase in the absolute neutrophil count in normal and suppressed mice. The therapeutic application of this hematopoietic modulator has been demonstrated in combination cyclophosphamide and bestatin therapeutic protocols. Because this indication for bestatin has only recently been recognized, few clinical studies have been undertaken utilizing appropriate surrogates of hematopoietic activity. However, preliminary clinical evidence of hematopoietic activity by this non-toxic dipeptide, as reviewed here, suggests that this may be an appropriate strategy for the treatment of myelosuppressed patients.

AB - Bestatin is a potent inhibitor of aminopeptidase, an enzyme found in abundance in the membrane of monocytes and macrophages. Following binding of bestatin to cells in the histiocytic lineage, the production of colony stimulating activity is upregulated (both in vitro and in vivo) with subsequent increases in hematopoietic and hematologic parameters. We report that the frequency and absolute numbers of CFU-GM as well as entry of CFU-GM into S phase (a measure of progenitor cell activity) is upregulated by treatment of animals with bestatin. This results in an increase in bone marrow cellularity in cyclophosphamide suppressed mice and an increase in the absolute neutrophil count in normal and suppressed mice. The therapeutic application of this hematopoietic modulator has been demonstrated in combination cyclophosphamide and bestatin therapeutic protocols. Because this indication for bestatin has only recently been recognized, few clinical studies have been undertaken utilizing appropriate surrogates of hematopoietic activity. However, preliminary clinical evidence of hematopoietic activity by this non-toxic dipeptide, as reviewed here, suggests that this may be an appropriate strategy for the treatment of myelosuppressed patients.

KW - bestatin / hematopoiesis / myelosuppression / CFU-GM

KW - bestatine / hématopoïèse / myelosuppression / CFU-GM

UR - http://www.scopus.com/inward/record.url?scp=0025173290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025173290&partnerID=8YFLogxK

U2 - 10.1016/0753-3322(90)90109-M

DO - 10.1016/0753-3322(90)90109-M

M3 - Article

C2 - 2224059

AN - SCOPUS:0025173290

VL - 44

SP - 85

EP - 91

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 2

ER -